Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes

International Journal of Cardiology

Volumn 107, Issue 1, 2006, Pages 11-20

  Zeymer, Uwe ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Acarbose; Cardiovascular; Impaired glucose tolerance; Postprandial hyperglycaemia; STOP NIDDM; Type 2 diabetes

Indexed keywords

ACARBOSE; CARBOHYDRATE; GLUCOSE; INSULIN;

ACUTE HEART INFARCTION; CARBOHYDRATE ABSORPTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DIABETES CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; EARLY DIAGNOSIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MEDICAL ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 28844492259     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.02.033     Document Type: Review

References (72)

1. H. King, R.E. Aubert, and W.H. Herman Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections Diabetes Care 21 1998 1414 1431
2. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
3. R. Donnelly, A.M. Emslie-Smith, I.D. Gardner, and A.D. Morris ABC of arterial and venous disease: vascular complications of diabetes BMJ 320 2000 1062 1066
4. M.I. Harris, R. Klein, T.A. Welborn, and M.W. Knuiman Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis Diabetes Care 15 1992 815 819
5. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 27 Suppl 1 2004 S5 S10
6. World Health Organization Definition, diagnosis and classification of diabetes mellitus and its complications Report of a WHO consultation: Part 1. Diagnosis and classification of diabetes mellitus 1999 Geneva 1 59
7. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Follow-up report on the diagnosis of diabetes mellitus Diabetes Care 26 2003 3160 3167
8. T.M. Wolever, J.L. Chiasson, and A. Csima Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose Diabetes Care 21 1998 336 340
9. N. Unwin, J. Shaw, P. Zimmet, and G. Alberti Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention Diabet Med 19 2002 1 17
10. M. Coutinho, H.C. Gerstein, Y. Wang, and S. Yusuf The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years Diabetes Care 22 1999 233 240
11. F.C. Sasso, O. Carbonara, and R. Nasti Glucose metabolism and coronary heart disease in patients with normal glucose tolerance JAMA 291 2004 1857 1863
12. DECODE Study Group Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies Diabetologia 42 1999 647 654
13. DECODE Study Group European Diabetes Epidemiology Group Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26 2003 688 696
14. M. Tominaga, H. Eguchi, H. Manaka, K. Igarashi, T. Kato, and A. Sekikawa Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study Diabetes Care 22 1999 920 924
15. M. Hanefeld, S. Fischer, and U. Julius Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up Diabetologia 39 1996 1577 1583
16. E. Barrett-Connor, and A. Ferrara Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study Diabetes Care 21 1998 1236 1239
17. R.P. Donahue, R.D. Abbott, D.M. Reed, and K. Yano Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program Diabetes 36 1987 689 692
18. B. Balkau, M. Shipley, and R.J. Jarrett High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study Diabetes Care 21 1998 360 367
19. K. Malmberg, A. Norhammar, H. Wedel, and L. Ryden Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study Circulation 99 1999 2626 2632
20. K. Malmberg, L. Ryden, and S. Efendic Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year J Am Coll Cardiol 26 1995 57 65
21. K. Malmberg Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group Br Med J 314 1997 1512 1515
22. K. Malmberg, A. Norhammar, and L. Ryden Insulin treatment post myocardial infarction: the DIGAMI study Adv Exp Med Biol 498 2001 279 284
23. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
24. M.J. Sheetz, and G.L. King Molecular understanding of hyperglycemia's adverse effects for diabetic complications JAMA 288 2002 2579 2588
25. T. Nishikawa, D. Edelstein, and X.L. Du Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404 2000 787 790
26. J.V. Hunt, R.T. Dean, and S.P. Wolff Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing Biochem J 256 1988 205 212
27. S. Suzuki, Y. Hinokio, and K. Komatu Oxidative damage to mitochondrial DNA and its relationship to diabetic complications Diabetes Res Clin Pract 45 1999 161 168
28. H. Lum, and K.A. Roebuck Oxidant stress and endothelial cell dysfunction Am J Physiol, Cell Physiol 280 2001 C719 C741
29. A. Ceriello, F. Mercuri, and L. Quagliaro Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress Diabetologia 44 2001 834 838
30. M. Hanefeld, C. Koehler, F. Schaper, K. Fuecker, E. Henkel, and T. Temelkova-Kurktschiev Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals Atherosclerosis 144 1999 229 235
31. T.S. Temelkova-Kurktschiev, C. Koehler, and W. Leonhardt Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors Diabetes Care 22 1999 333 338
32. D.H. O'Leary, J.F. Polak, R.A. Kronmal, T.A. Manolio, G.L. Burke, and S.K. Wolfson Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group N Engl J Med 340 1999 14 22
33. M.L. Bots, A.W. Hoes, P.J. Koudstaal, A. Hofman, and D.E. Grobbee Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study Circulation 96 1997 1432 1437
34. National Heart Lung and Blood Institute Third report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 2001
35. P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, and O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
36. K. Matsumoto, Y. Sera, Y. Abe, T. Tominaga, Y. Yeki, and S. Miyake Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes Diabetes Res Clin Pract 64 2004 225 228
37. K. Esposito, D. Giugliano, F. Nappo, and R. Marfella Regression of carotid atherosclerosis by control of postprandial hyperglycaemia in type 2 diabetes mellitus Circulation 110 2004 214 219
38. C.L. Meinert, G.L. Knatterud, T.E. Prout, and C.R. Klimt A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: II. Mortality results Diabetes 19 1970 789 830
39. J.A. Colwell The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the veterans affairs cooperative study on glycemic control and complications in NIDDM Ann Intern Med 124 1996 131 135
40. UK Prospective Diabetes Study Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes Lancet 1998 352 854
41. H. Laube An update of its therapeutic use in diabetes treatment Clin Drug Investig 22 2002 141 156
42. J. Hoffmann, and M. Spengler Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study Diabetes Care 17 1994 561 566
43. J. Hoffmann, and M. Spengler Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study Am J Med 103 1997 483 490
44. W.C. Knowler, E. Barrett-Connor, and S.E. Fowler Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
45. J. Tuomilehto, J. Lindstrom, and J.G. Eriksson Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 2001 1343 1350
46. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 290 2003 486 494
47. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Lancet 359 2002 2072 2077
48. U. Zeymer, A. Schwarzmaier-D'Assie, D. Petzinna, and J. Chiasson Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance. Results of the randomised STOP-NIDDM trial ECG substudy Eur J Cardiovasc Prev Rehabil 11 2004 412 415
49. M. Hanefeld, J.L. Chiasson, C. Koehler, E. Henkel, F. Schaper, and T. Temelkova-Kurktschiev Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance Stroke 35 2004 1073 1078
50. M. Hanefeld, M. Cagatay, T. Petrowitsch, D. Neuser, D. Petzinna, and M. Rupp Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies Eur Heart J 25 2004 10 16
51. P. Rosenbaum, R.B. Peres, M.T. Zanella, and S.R. Ferreira Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters Braz J Med Biol Res 35 2002 877 884
52. J.H. Rosenthal, and H. Mauersberger Effects on blood pressure of the alpha-Glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus Clin Drug Investig 22 2002 695 701
53. G.M. Reaven, H. Lithell, and L. Landsberg Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system N Engl J Med 334 1996 374 381
54. R. Scott, C.J. Lintott, P. Zimmet, L. Campbell, K. Bowen, and T. Welborn Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? Diabetes Res Clin Pract 43 1999 179 185
55. S. Salman, F. Salman, and I. Satman Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes Curr Med Res Opin 16 2001 296 306
56. S. Kado, T. Murakami, and A. Aoki Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus Diabetes Res Clin Pract 41 1998 49 55
57. T. Kawamura, G. Egusa, and R. Fujikawa Effect of acarbose on glycemic control and lipid metabolism in patients with non-insulin-dependent diabetes mellitus Curr Ther Res 59 1998 97 105
58. E. Ferrannini, A. Natali, B. Capaldo, M. Lehtovirta, S. Jacob, and H. Yki-Jarvinen Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR) Hypertension 30 1997 1144 1149
59. M. Tilly-Kiesi, P. Knudsen, L. Groop, and M.R. Taskinen Hyperinsulinemia and insulin resistance are associated with multiple abnormalities of lipoprotein subclasses in glucose-tolerant relatives of NIDDM patients. Botnia study group J Lipid Res 37 1996 1569 1578
60. S. Agewall, B. Fagerberg, S. Attvall, I. Wendelhag, V. Urbanavicius, and J. Wikstrand Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk Stroke 26 1995 956 960
61. H. Delgado, T. Lehmann, E. Bobbioni-Harsch, J. Ybarra, and A. Golay Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients Diabetes Metab 28 2002 195 200
62. A. Calle-Pascual, J. Garcia-Honduvilla, P.J. Martin-Alvarez, J.R. Calle, and J.P. Maranes Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo Diabetes Metab 22 1996 201 202
63. J.L. Chiasson, R.G. Josse, and L.A. Leiter The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance Diabetes Care 19 1996 1190 1193
64. G.S. Meneilly, E.A. Ryan, and J. Radziuk Effect of acarbose on insulin sensitivity in elderly patients with diabetes Diabetes Care 23 2000 1162 1167
65. A. Ceriello, C. Taboga, and L. Tonutti Post-meal coagulation activation in diabetes mellitus: the effect of acarbose Diabetologia 39 1996 469 473
66. D. Tschoepe Decreased fibrinogen by treatment with the alpha-glucosidase inhibitor acarbose Orlando, Florida: American Diabetes Association 64th scientific sessions June 4-8, Orlando, Florida 2004 Abstract no. 766-P
67. Heart Protection Study Collaborative Group MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
68. K. Pyorala, T.R. Pedersen, J. Kjekshus, O. Faergeman, A.G. Olsson, and G. Thorgeirsson Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 20 1997 614 620
69. R.B. Goldberg, M.J. Mellies, and F.M. Sacks Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The care investigators Circulation 98 1998 2513 2519
70. The LIPD Study Group Prevention of CV events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group N Engl J Med 339 1998 1349 1357
71. Hope Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators Lancet 355 2000 253 259
72. A. Norhammar, A. Tenerz, and G. Nilsson Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study Lancet 359 2002 2140 2144